Caris Life Sciences, Inc. (CAI)

Ticker: CAI
Exchange: NASDAQ
Currency: USD
Country: United States
Security: Common Stock
Industry roles: AI applications

Listing source history

Listing data synced 2026-04-16. This is the listing record date, separate from quote updates.

AI supply-chain role

Builds AI models, software or applications for end users and enterprises.

Sources may describe historical activity or future plans. Source publication dates do not confirm current deliveries. ✓ Verified means one of the two companies confirmed the relationship in its own filing, investor-relations release or official announcement, and the source link was checked on the review date.

No verified relationships available yet.

Latest earnings

2026-08-05

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance ↗

Latest company announcements

2026-08-05 · SECCAI · 10-Q filing ↗
2026-09-14 · SECCAI · 8-K filing ↗
2026-09-08 · IRCaris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect ↗
2026-09-02 · IRCaris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer ↗

Business and financials

Estimated market cap

9.04B USD

As of 2026-10-23

Calculation details

Latest cached closing price × SEC reported shares outstanding.

Share count as of 2026-08-03

Filed 2026-08-05 ↗

Annual financials

Annual report for the year ended 2025-12-31. These are reported annual figures, not trailing twelve-month estimates.

What the company says it does

We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.

Excerpt from Item 1 — Business; filed 2026-03-03. May be shortened.

Read the 10-K annual report ↗

Revenue: 812.03M USD; 2025-01-01 to 2025-12-31
Filed 2026-03-03 ↗
Net income: -68.09M USD; 2025-01-01 to 2025-12-31
Filed 2026-03-03 ↗
Diluted EPS: -3.22 USD / share; 2025-01-01 to 2025-12-31
Filed 2026-03-03 ↗
Operating cash flow: 83.16M USD; 2025-01-01 to 2025-12-31
Filed 2026-03-03 ↗
Cash and equivalents: 796.27M USD; As of 2025-12-31
Filed 2026-03-03 ↗
Total assets: 1.13B USD; As of 2025-12-31
Filed 2026-03-03 ↗

Source: SEC Company Facts. Checked 2026-10-19. Data is refreshed in the background. Missing or ambiguous figures are left unavailable.

Showing a previously fetched snapshot. A recent refresh has not completed.

Loading SEC business and financials…

Peer comparison

Applications · US-listed · 10 companies in the recorded group

Same-market companies with the same recorded industry role. Coverage is partial; this is not a full-industry ranking.

Sample coverage 8/10Your company’s sample rank 8/8As of 2026-10-23

Values in USD

Market caps are estimates based on cached closing prices and disclosed share counts.

Sample mean: 774.56B
Sample median: 139.59B

Analyst views

Loading views…

Loading your outlook…

Analyst posts

Publish a view

Loading…

Caris Life Sciences, Inc. (CAI)

Industry

Investment themes

AI supply-chain role

Latest earnings

Latest company announcements

Business and financials

Annual financials

Peer comparison

Analyst views

Analyst posts

Industry

Investment themes

AI supply-chain role

Business and financials

Annual financials

Peer comparison